SCHEMBL1248412

SCHEMBL1248412

CCOC(=O)Nc1ccc(C=O)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.54
NPC1 O15118 5/20 0.54
ALDH1A1 P00352 5/20 0.54
HPGD P15428 5/20 0.54
HSD17B10 Q99714 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 2/20 0.54
CYP1A2 P05177 4/20 0.52
CYP2C9 P11712 4/20 0.52
CYP2C19 P33261 4/20 0.52
CYP2D6 P10635 2/20 0.52
CYP3A4 P08684 1/20 0.52
HTT P42858 1/20 0.52
MAPT P10636 3/20 0.51
LMNA P02545 2/20 0.51
MAPK1 P28482 2/20 0.51
POLB P06746 1/20 0.51
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
CASP3 P42574 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9472298 0.84 ALDH1A1 (0.57) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL11440992 0.82 POLB (0.62) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL377917 0.79 ALDH1A1 (0.54) RAB9ANPC1ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL29958034 0.79 ALDH1A1 (0.54) RAB9ANPC1ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL1250097 0.78 RAB9A (0.67) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL10192133 0.78 NPC1 (0.57) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL7565510 0.78 RAB9A (0.71) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL6004359 0.78 RAB9A (0.58) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL473082 0.76 NLRP3 (0.66) RAB9ANPC1ALDH1A1HPGDHSD17B10
SCHEMBL28175286 0.76 ALDH1A1 (0.38) RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074089-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-09-18 EP disclosed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
EP-2074089-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-07-01 EP disclosed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 RAB9A 1888/4885NPC1 32/4885ALDH1A1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.